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Abstract
The prevalence and frequency of the dihydrofolate reductase (dhfr) and dihydropteroate synthetase
(dhps) mutations associated with sulfadoxine–pyrimethamine (SP) resistance at 13 sentinel
surveillance sites in southern Mozambique were examined regularly between 1999 and 2004.
Frequency of the dhfr triple mutation increased from 0.26 in 1999 to 0.96 in 2003, remaining high
in 2004. The dhps double mutation frequency peaked in 2001 (0.22) but declined to baseline levels
(0.07) by 2004. Similarly, parasites with both dhfr triple and dhps double mutations had increased
in 2001 (0.18) but decreased by 2004 (0.05). The peaking of SP resistance markers in 2001
coincided with a SP–resistant malaria epidemic in neighboring KwaZulu-Natal, South Africa. The
decline in dhps (but not dhfr) mutations corresponded with replacement of SP with artemether–
lumefantrine as malaria treatment policy in KwaZulu-Natal. Our results show that drug pressure
can exert its influence at a regional level rather than merely at a national level.
Copyright © 2008 by The American Society of Tropical Medicine and Hygiene
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INTRODUCTION
Malaria-related morbidity and mortality has risen in Africa, principally because of
increasing resistance to chloroquine and sulfadoxine–pyrimethamine (SP) in Plasmodium
falciparum.1,2 The economic impact of malaria is massive, costing Africa an estimated US$
12 billion per annum.3 Malaria control programs that effectively control both the mosquito
vector and the falciparum parasite can reduce the malaria burden substantially.4–6 The
Lubombo Spatial Development Initiative (LSDI) initiated in 1999, is a cross-border
collaboration between the governments of Mozambique, Swaziland, and South Africa, to
develop the Lubombo region into a globally competitive economic zone (Figure 1). As
malaria control is a necessary precursor to economic development, this is a core component
of the initiative and comprises two arms: vector control through widespread community-
based, indoor residual insecticide spraying (IRS), and parasite control through the phased
implementation of effective artemisinin-based combination treatment of definitively
diagnosed malaria cases.7
As the emergence of drug resistance is a potential threat to the success of the LSDI,
population-based antimalarial resistance surveillance was conducted from the start of the
intervention. First line malaria treatment policy varied across the LSDI region (Figure 1). In
KwaZulu-Natal (KZN), a province in South Africa, SP replaced the chloroquine treatment
policy in 1988, following a high prevalence of treatment failures associated with the
emergence of chloroquine resistant parasites.8,9 An SP in-vivo therapeutic efficacy study
with a 42-day follow-up period conducted in KZN 12 years after SP introduction found
adequate clinical and parsitological response in only 11% of patients with uncomplicated
falciparum malaria.5,10 This prompted a treatment policy change to the artemisinin-based
combination therapy (ACT), artemether–lumefantrine, in January 2001.5 In Mozambique,
chloroquine was the first-line treatment and SP the second-line treatment until 2004, when
the LSDI started phased implementation of the ACT, artesunate plus SP, as the first-line
treatment in Maputo Province. This ACT has now become Mozambique’s national malaria
treatment policy.
Accumulation of point mutations in the 2 enzyme systems targeted by SP, namely,
dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps), confer resistance to
pyrimethamine and sulfadoxine, respectively,11,12 with higher levels of treatment failure
observed with multiple mutations.13,14 The combination of 3 dhfr point mutations at codons
108, 51, and 59 and 2 dhps mutations at codons 437 and 540 is strongly correlated with SP
treatment failure.15 Emergence of SP resistance in southern and east Africa is a result of a
combination of increased drug pressure, applied through SP use for malaria treatment, and
migration of resistant genes from areas of established resistance.16 In the case of dhfr, the
highly resistant triple-mutant allele has been shown to have originated in southeast Asia.17
The dhps double-mutant allele found throughout the southeast African region is descended
from a common ancestral lineage,16 although its site of origin remains to be identified.
To explore the effect of gene flow on the development of resistance in neighboring countries
with different malaria treatment policies, we analyzed the prevalence and frequency of dhfr
and dhps alleles between 1999 and 2004 in the LSDI areas in southern Mozambique closest
to KZN in South Africa (Figure 1).
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MATERIALS AND METHODS
Study population and blood sample collection
Finger-prick blood samples were collected during systematic community-based sampling of
120 children (of age 2–15 years) at each of the 13 sentinel sites in LSDI zones 1, 1A, and 2A
in Maputo Province, southern Mozambique (Figure 1). These surveys commenced in the
1999–2000 malaria-transmission season and were repeated regularly.7 Baseline P.
falciparum prevalence was 63.5% in Zone 1, 88% in Zone 1A, and 76% in Zone 2A.7
Capillary blood samples were blotted on filter paper [Whatman filter paper No. 1; Merck
Laboratory Supplies (Pty) Ltd., Durban, South Africa] and individually stored at room
temperature in zip-lock packets containing desiccant. Ethical approval for this study was
obtained from South African Medical Research Council and the Maputo Province
Directorate of Health, Mozambique. Blood samples were only taken after full consent from
a parent/guardian had been obtained.
Sample preparation and analysis
Parasite DNA was extracted using the Chelex method18 from the blood spots of participants
found to be rapid-test positive (ICT, Global Diagnostics, Cape Town, South Africa, and Kat
Quick, Kat Medical, Johannesburg, South Africa, which detect P. falciparum histidine-rich
protein 2). Once a sample was confirmed as P. falciparum positive by nested PCR,19
polymorphism analyses of dhfr and dhps genes were conducted. Primers, PCR amplification
conditions, and restriction endonucleases used to detect polymorphisms in the dhfr (codons
51, 59, 108, and 164) and dhps (codons 436, 437, 540, and 581) genes have been described
previously.20,21 Digestion products separated on a 2% agarose gel using electrophoresis
were visualized and photographed using a MiniBIS documentation system (Bio-
Systematica, Ceredigion, Wales, UK). Codons were classified as either pure sensitive, pure
mutant, or mixed (both mutant and sensitive genotypes present in an individual sample).
Genotyping was run in duplicate, with a third assay being performed on any discordant
results.
Prevalence of mutant genotypes
When overall prevalence of infections with mutant genotypes was calculated, codons with
mixed genotypes were grouped with pure mutant codons.
Frequency of mutant genotypes
For mutant allele frequency calculations, the mixed codons were reclassified as either
sensitive or mutant, depending on which allele was more dominant (visually darker band on
the gel). When the two alleles were equally dominant (similar visual intensities on the gel),
the sample was excluded from the frequency (but not prevalence) analyses as the actual
haplotype could not be determined.
Statistical analysis
Statistical analysis was preformed using Stata 9.0 (Stata Corp., College Station, TX).
Univariate analysis and multiple variable logistic regression were carried out to determine
whether any of the prospectively defined factors (namely, age, gender, fever, asexual
parasite prevalence at the given sentinel site, zone, year) were significantly associated with
mutation frequency and prevalence. Statistical inference took account of within-sentinel site
correlations of mutational markers. Confidence limits were set at 95%.
Raman et al. Page 3
Am J Trop Med Hyg. Author manuscript; available in PMC 2013 August 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
RESULTS
A total of 6,179 blood samples were collected over the study period, 2,175 (35%) of which
were rapid-test positive for P. falciparum. DNA was extracted from 1,215 randomly selected
rapid-test positive samples collected in 1999, 2001, 2003, and 2004, 1,114 (92%) of which
were confirmed to be P. falciparum positive by PCR. The falciparum-positive samples were
taken from children with a median age of 7 (IQR 4–10) years, 48.4% were female and 4.9%
were febrile (axillary temperature ≥ 37.5°C). Mixed genotypes were detected in 243 of
1,114 (21.8%) samples. Of the samples with mixed genotypes, 194 (79.8%) could not be
haplotyped.
The dhfr 164 mutation was not found in any of the samples analyzed. The dhps 436 and 581
mutations were rare, with prevalence of 0.01% and < 0.001%, respectively.
Baseline prevalence of the dhfr triple mutation differed markedly across the 3 zones (47.5%
in Zone 1, 9% in Zone 1A, and 18.4% in Zone 2A). The greatest variation in sentinel site
dhfr triple prevalence was detected in Zone 1, where the prevalence ranged from 5% to 65%.
The prevalence of the dhfr triple mutation across all 3 zones increased from 26% in 1999 to
96% in 2003 (OR: 77.3; 95% CI: 29.4–202.9; P < 0.0001), with prevalences remaining
essentially unchanged thereafter (Figure 2A).
Baseline prevalence of the dhps double mutant was relatively low across all 3 zones (11% in
Zone 1, 5% in Zone 1A, and 11% in Zone 2A), with little variation in prevalence between
sentinel sites. Prevalence of the dhps double haplotype increased significantly between 1999
and 2001, from 9.1% to 36.3% (OR: 5.70; 95% CI: 2.84–11.43; P < 0.0001; Figure 2B).
Similarly, the prevalence of parasites with both the dhfr triple and dhps double mutation,
sometimes referred to as the “quintuple” genotype, increased from 4% in 1999 to 28% in
2001 (OR: 5.73; 95% CI: 2.12–15.50; P = 0.001; Figure 2C). However, unlike the triple dhfr
mutation, there had been a decline in the prevalence of the dhps double (OR: 0.22; 95% CI:
0.08–0.59; P = 0.004) and the quintuple mutants (OR: 0.33; 95% CI: 0.13–0.83; P = 0.021)
between 2001 and 2004 (Figures 2B and 2C, respectively).
Allelic frequencies of the dhfr triple and dhps double haplotypes and quintuple genotype
mirrored the trends observed in the prevalence analyses. These frequencies are reported by
zone and year in Table 1.
Univariate analysis showed that the occurrence of the dhfr triple mutant allele was
negatively associated with site specific asexual parasite prevalence (OR: 0.96 per % change
in site asexual parasite prevalence; 95% CI: 0.93–0.98; P = 0.001) and age (OR: 0.92 per
year of age; 95% CI: 0.88–0.97; P = 0.004). After adjusting for survey year, multiple logistic
regression analysis was able to confirm that the dhfr triple mutation prevalence was
independently negatively associated with age (OR: 0.92; 95% CI: 0.88–0.96; P = 0.001) but
not with the asexual-stage parasite prevalence of a sentinel site.
The prevalence of the quintuple genotype was higher in children who were febrile
(temperature ≥ 37.5°C; OR: 1.32; 95% CI: 1.03–1.68; P = 0.03) and decreased with
increasing age (OR: 0.94 per year of age; 95% CI: 0.88–1.0; P = 0.048). None of the other
predefined explanatory variables was found to be associated with the prevalence of the
double dhps or quintuple mutations. Results were similar when mixed genotype infections
were excluded and allelic frequencies rather than prevalence were analyzed.
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DISCUSSION
Despite high levels of therapeutic failure associated with chloroquine resistance,
Mozambique continued to use chloroquine as first-line treatment and SP as the second-line
treatment until 2004.22 Given this limited SP use within southern Mozambique, it is not
surprising that the prevalence of dhfr and dhps mutations was relatively low in 1999.
However, by 2001 all markers associated with SP resistance had increased markedly in
southern Mozambique. This is most likely a consequence of increased SP drug pressure
within the region. Neighboring KZN experienced a severe SP-resistant malaria epidemic
peaking in 2000, when 89% of patients with uncomplicated malaria failed SP treatment
within 42 days.5,10 In 1999, the population-wide frequency of the dhfr triple and dhps
double mutants in northern KZN was 0.38 and 0.15, respectively.16 However, among
symptomatic malaria cases during the same year, frequencies were considerably higher; dhfr
triple mutant allele was 0.62, and dhps double mutant was 0.47.16
This reduced SP efficacy resulted in the KZN Ministry of Health becoming the first in
Africa to implement an artemisinin-based combination therapy (ACT) drug policy when
artemether–lumefantrine replaced SP as the first-line antimalarial in January 2001.5 After
this policy change in KZN, prevalences of both the dhps double and quintuple mutations in
southern Mozambique began to decline, reaching baseline values by 2004. An in vivo SP
therapeutic efficacy study with a 42-day follow-up period conducted in Zone 1 in 2003
found adequate clinical and parasitological response in 87.7% of the patients with
uncomplicated malaria (K. I. Barnes, unpublished data). However the prevalence of the dhps
double in symptomatic children in a neighboring district, in 200423 was higher than the
levels observed in this study. Other than the change in malaria treatment policy in KZN,
there were no major changes in SP drug use in the region that could explain the significant
increase and then decrease in the dhps double and quintuple genotypes that we observed.
It seems probable that once the high SP drug pressure was removed, sulfadoxine-sensitive
parasites began to re-emerge in southern Mozambique. This observation supports the view
that the mutant allele carries some fitness cost which is disadvantageous in the absence of
widespread drug use.24 Although this has not been observed before in the context of the
dhps double haplotype with decreased sulfadoxine use, it appears to be the case for the Pfcrt
mutation when chloroquine use is diminished.25
In contrast, the dhfr triple mutation prevalence did not decline once SP drug pressure from
KZN was markedly reduced. Instead the mutation continued to increase almost to fixation
within the population, a finding seen previously in Mozambique.23 There are 3 possible
explanations for this. Firstly, dhfr triple mutants may have undergone compensatory
mutations which minimized the reduced fitness effect of the dhfr mutations,26 thereby
allowing the mutants to thrive in the absence of SP drug pressure, a trend observed in South
East Asia.27 Secondly, there may have been insufficient sensitive parasites remaining in the
population for a recovery once the drug pressure is removed. Our data show that sensitive
parasites were uncommon in the study area after 2001 (prevalence of 3% in 2003 and 8% in
2004). They were predominantly found in older age groups, who may be less likely to
receive treatment once partial immunity is acquired. Thirdly, the use of antifolate–
sulfonamide combinations, like Co-trimoxazole, as prophylaxis against opportunistic
infections in HIV/AIDS patients,15,28 may have contributed to the selection for the dhfr
triple mutant. In such a scenario, we would expect to see a similar increase in dhps double
mutants, a trend not observed in this study.
The presence of the dhfr triple haplotype results in more than a 1,000-fold increase in the
pyrimethamine IC50 in vitro.29 Given the high frequency of the dhfr triple mutant in
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southern Mozambique, it would seem that SP therapeutic efficacy is primarily being
provided by sulfadoxine, although pyrimethamine may still be exerting some synergistic
benefit. The therapeutic efficacy of sulfonamide monotherapy has previously been shown.30
A policy shift to ACTs is widely advocated as it is expected that 2 drugs with differing
modes of action would increase therapeutic efficacy, and the artemisinins specifically would
decrease malaria transmission, thus reducing the risk of resistance spreading.31 Phased
implementation of the artemisinin-based combination, artesunate plus SP, began in LSDI
districts in southern Mozambique in 2004. This ACT has since become the Mozambican
national malaria treatment policy.
Unfortunately, the benefits of combination therapy are negated by inclusion of an ineffective
partner drug.32 At present, there is no direct evidence that the addition of artesunate to SP,
even when SP remains reasonably effective, could avert the spread of SP resistance.
Resistance to SP spreads particularly rapidly, mainly due to 2 factors. Firstly, the selection
pressure exerted by SP’s relatively long elimination half-life33 and secondly, patients
carrying resistance parasites tend to have enhanced gametocyte carriage and are more
infectious to mosquitoes than patients with wild type parasites.34,35 Close surveillance of
sulfadoxine resistance markers and the highly pyrimethamine (and dapsone)-resistant 164
dhfr mutation is essential now that artesunate plus SP is being widely deployed in the
region, to ensure that artesunate does not in effect become a monotherapy.
Results from this study highlight the importance of considering the regional impact of
neighboring countries’ drug policies. Although never first-line treatment in Mozambique, SP
use in KZN has strongly influenced SP-resistance marker prevalence in southern
Mozambique, with most P. falciparum isolates now carrying the dhfr triple mutation.
Although dhps mutations are currently uncommon, increased SP drug pressure is likely to
rapidly select for sulfadoxine-resistant parasites. This has far-reaching consequences when
considering new drug policies involving SP and related antifolates such as chlorproguanil–
dapsone. Ongoing monitoring of dhfr and dhps mutation prevalence and the therapeutic
efficacy of the SP-containing combination would be imperative to ensure effective treatment
policies in the region.
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Figure 1.
Zones and sentinel sites of the Lubombo Spatial Development Initiative malaria control
programme.
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Figure 2.
Prevalence of dhfr triple (A), dhps double (B) and quintuple (C) mutations by study zone
and year.
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Table 1
dhfr triple and dhps double and quintuple mutation frequency, by zone and year
Mutant type Year Total Zone 1 Zone 1A Zone 2A OR 95% CI P value
1999 0.26 (61/238) 0.48 (40/84) 0.09 (7/78) 0.18 (14/76) 1
2001 0.62 (197/320) 0.59 (102/174) 0.69 (79/115) 0.52 (16/31) 4.65 1.69–12.81 0.005
2003 0.96 (213/221) 0.96 (49/51) 0.97 (105/108) 0.95 (59/62) 77.36 29.42–202.89 0.000
dhfr triple 2004 0.85 (175/206) 0.89 (47/53) 0.80 (87/109) 0.93 (41/44) 16.38 7.04–38.11 0.000
1999 0.07 (16/237) 0.06 (5/83) 0.05 (4/78) 0.09 (7/76) 1
2001 0.22 (80/369) 0.19 (35/186) 0.25 (38/151) 0.22 (7/32) 3.82 2.19–6.670 0.000
2003 0.06 (13/212) 0.04 (2/50) 0.08 (8/105) 0.05 (3/57) 0.90 0.42–191 0.780
dhps double 2004 0.07 (14/217) 0.05 (3/56) 0.09 (10/117) 0.02 (1/44) 0.95 0.33–2.71 0.925
1999 0.04 (9/237) 0.06 (5/83) 0.03 (2/78) 0.03 (2/76) 1
2001 0.18 (47/256) 0.14 (19/137) 0.26 (25/96) 0.13 (3/24) 5.69 2.41–13.42 0.000
2003 0.06 (13/212) 0.04 (2/50) 0.08 (8/105) 0.05 (3/57) 1.66 0.68–4.03 0.254
SP quintuple 2004 0.05 (13/201) 0.06 (3/53) 0.09 (9/106) 0.02 (1/42) 1.75 0.71–4.34 0.216
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